Clinical Trials Search | Clareo Health

RECRUITINGPhase 2

Oral Bevacizumab-800CW and Cetuximab-800CW Administration to Detect Early Esophageal Adenocarcinomas

NCT05745857

Previous studies have confirmed the great potential of quantitative fluorescence molecular endoscopy (qFME) when looking at additional lesion detection initially missed by high-definition white light endoscopy (HD-WLE) for surveillance of Barrett's esophagus.

Barrett's Esophagus Without DysplasiaBarrett Oesophagitis With DysplasiaEsophageal Adenocarcinoma

University Medical Center Groningen25 participantsStarted Sep 2023

Groningen, Provincie Groningen, Netherlands

Active Not Recruiting

Cell Marker Predictors in Barrett's Esophagus

NCT03316053

The purpose of this study is to analyze biopsied tissue samples for changes in cells and genes involved in Barrett's Esophagus.

Barrett's Esophagus Without Dysplasia

The Guthrie Clinic25 participantsStarted Nov 2017

Sayre, Pennsylvania, United States

COMPLETED

A Liquid Biopsy for High-risk Pre-cancer Screening of Esophageal Adenocarcinoma

NCT06381583

This study aims to develop a highly sensitive, specific, and cost-effective blood assay for the early detection of esophageal adenocarcinoma and its precursor lesions, using advanced machine learning and state-of-the-art biological analyses.

Esophagus CancerEsophageal Cancer StageEsophageal Cancer+18 more

City of Hope Medical Center658 participantsStarted Apr 2023

Duarte, California, United States

Filters

Oral Bevacizumab-800CW and Cetuximab-800CW Administration to Detect Early Esophageal Adenocarcinomas

Cell Marker Predictors in Barrett's Esophagus

A Liquid Biopsy for High-risk Pre-cancer Screening of Esophageal Adenocarcinoma

Oral Bevacizumab-800CW and Cetuximab-800CW Administration to Detect Early Esophageal Adenocarcinomas

Cell Marker Predictors in Barrett's Esophagus

A Liquid Biopsy for High-risk Pre-cancer Screening of Esophageal Adenocarcinoma